Aquestive(US:AQST) TMX Newsfile·2026-03-15 12:45Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's NDA for Anaphylm, with a deadline for investors to seek lead plaintiff status in a class action lawsuit set for May 4, 2026 [2][4]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is publicly traded on NASDAQ under the ticker AQST [2]. - The company is currently facing legal scrutiny regarding its New Drug Application (NDA) for Anaphylm, which has been flagged by the FDA for deficiencies [5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Aquestive, alleging that the company and its executives made false or misleading statements and failed to disclose critical information regarding the NDA [4]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members, with the option for any member to move the court to serve as lead plaintiff [6]. Group 3: Stock Market Impact - Following the announcement of deficiencies in the NDA by the FDA, Aquestive's stock price dropped by $2.30, or 37.04%, closing at $3.91 per share on January 9, 2026 [5]. Group 4: Call for Information - Faruqi & Faruqi encourages individuals with information regarding Aquestive's conduct, including whistleblowers and former employees, to come forward [7].